ABCB1 and cancer: Meanwhile, our present work revealed that the presentative compound D1 could significantly reverse the drug resistance of MCF-7/ADR and K562/ADR cells to DOX and indicated that D1 had the potential to develop as a good DOX and other chemotherapeutic agent sensitizer for ABCB1 transporter-mediated MDR in clinical cancer treatment.